Subscribe to our Blog
Subscribe to our Blog
Our World ADC talk shows how trispecific antibodies can get more payload into tumor cells while limiting off-tumor toxicity, with data from ...
Choosing a bispecific format is one decision. Choosing who builds the molecule, and on what terms, is a different one. Here's a look at the ...
Most antibody-drug conjugates hit one target. Real tumors aren't that cooperative. Here's what a third arm changes, where the evidence sits ...
Engineering a bispecific antibody lead candidate involves thousands of options within two high-level approaches. We examine the trade-offs ...
Bispecific antibodies are made by preparing the target, finding strong binders, assembling them into one molecule, and then purifying and ...
For transient proof-of-concept work, anti-CH1 capture with optimized DNA ratios is faster and cheaper than Protein A, which pays off once ...
The traditional antibody discovery paradigm relies on animal immunization (WT or transgenic). It is a proven process but one with lengthy ...
A trispecific antibody binds three targets at once, which opens up biology two arms can’t reach. Typical multispecific engineering ...
Bispecific antibodies engage two targets with one molecule, and how well a platform handles the underlying assembly problem decides whether ...
Get new resources, insights, and platform updates right in your inbox. Unsubscribe anytime.
Only a few emails per month. No spam.